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Clinical trials of beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase
inhibitors in heart failure have demonstrated a reduction in survival in treated patients despite
initial inotropic responses. These findings have led many to infer that activation of the
mechanisms through which contractility is increased has deleterious effects on failing
myocardium. It should be remembered, however, that these agents act proximately by raising
intracellular cyclic adenosine monophosphate (cAMP) content and stimulating protein
phosphorylation by cAMP-dependent protein kinase, and that the proteins whose phosphor-
ylation contributes to the inotropic responses may be different from the proteins whose
phosphorylation contributes to the reduction in survival. Evidence in support of the latter
interpretation is presented, and potential therapeutic approaches through which the phos-
phorylation of different proteins might be selectively affected are considered. (J Am Coll
Cardiol 1999;34:318–24) © 1999 by the American College of Cardiology
Cyclic adenosine monophosphate (cAMP)-mediated signal
transduction figures prominently in the pathophysiology
of heart failure (for review, see [1]). A decrease in beta1-
adrenergic receptor density and increases in beta-adrenergic
receptor kinase, G-alphai and nucleoside diphosphate ki-
nase activity contribute to an impairment in cAMP gener-
ation and a reduction in intracellular cAMP content in
failing myocardium (2–5). There are several reasons to
believe that the consequent decrease in cAMP-dependent
protein phosphorylation contributes to the diminished con-
tractility and pathologic dilation characteristic of failing
hearts (Fig. 1). Phosphorylation of Ca21 channels in the
sarcolemma and sarcoplasmic reticulum by cAMP-
dependent protein kinase increases their open probability,
resulting in increases in Ca21 influx across the plasma
membrane and Ca21 release from intracellular stores during
systole (6,7). Phosphorylation of phospholamban, a protein
that associates with the Ca21-transporting adenosine
triphosphatase of the sarcoplasmic reticulum, stimulates
Ca21 sequestration by that organelle during diastole; phos-
phorylation of troponin I reduces the Ca21 sensitivity of the
actin-activated myosin adenosine triphosphatase of the
contractile filaments (8,9). A reduction in cAMP content
could therefore reduce the amplitude of intracellular Ca21
transients and the extent of contraction and relaxation in
cardiac myocytes. Phosphorylation of cAMP-response
element-binding proteins (CREBs) by cAMP-dependent
protein kinase activates the transcription of genes contain-
ing cAMP response elements (10). Precisely which genes in
cardiac myocytes are regulated by CREB phosphorylation is
unknown, but transgenic mice expressing a dominant neg-
ative (i.e., nonphosphorylatable) CREB develop a dilated
cardiomyopathy that very closely resembles the human
disease (11).
In view of these actions of cAMP in cardiac myocytes, it
would be reasonable to expect agents that increase intracel-
lular cAMP content to have beneficial effects in patients
with heart failure. One therapeutic approach based upon
this reasoning is the administration of agents that stimulate
cAMP formation. Beta-adrenergic receptor agonists such as
noradrenaline, adrenaline, dopamine and dobutamine have
major inotropic effects in patients with heart failure (12). A
trial of intermittent intravenous infusion of dobutamine was
halted prematurely, however, because of an increase in
mortality in treated patients (13). Xamoterol, a partial
beta1-adrenergic receptor agonist, confers hemodynamic
and symptomatic benefits in patients with heart failure, but
its chronic administration likewise increases mortality in
treated patients (14). Another approach is the use of agents
that raise cAMP content in cardiac myocytes by inhibiting
its breakdown by cyclic nucleotide phosphodiesterases. En-
zymes in the PDE3 family of cyclic nucleotide phosphodi-
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esterases, which hydrolyze both cAMP and cyclic guanosine
monophosphate, constitute the principal high affinity
cAMP phosphodiesterase activity in cardiac muscle (15,16).
In early clinical trials, PDE3 inhibitors—for example, am-
rinone, milrinone and enoximone—were shown to improve
cardiac index and lower pulmonary capillary pressure in
patients with heart failure. Although some of these effects
might have been attributable to concomitant vasodilation
resulting from increases in cyclic guanosine monophosphate
content in vascular smooth muscle myocytes, myocardial
contractility, when measured, was clearly increased by
PDE3 inhibition (17–21). In long-term clinical trials, how-
ever, the hemodynamic improvements seen early in therapy
were typically not sustained, and meta-analysis demon-
strated an increase in mortality of about 40% after several
months of treatment (22–27). The reason for the increase in
mortality among patients treated with beta-adrenergic re-
ceptor agonists and PDE3 inhibitors was never established,
although in one trial an increase in ventricular arrhythmias
in treated patients was noted (24).
In the meantime, other investigators, viewing the abnor-
malities in cAMP-mediated signal transduction in failing
myocardium from a different perspective, pursued a diamet-
rically different approach. Guided by the notion that the
high serum catecholamine levels seen in patients with heart
failure are toxic and that changes in the level and function of
proteins involved cAMP-mediated signal transduction con-
stituting a compensatory response, they hypothesized that
treatment with beta-adrenergic receptor antagonists might
interrupt the process and thereby improve outcomes. Two
decades of research culminated in prospective studies dem-
onstrating that treatment with beta-adrenergic receptor
antagonists does indeed increase survival and ultimately
improve ventricular function in patients who can tolerate
the drugs (28–30).
Taken together, the results of these trials have had a
major impact on our current understanding of heart failure
and its therapy. They have reinforced the concept that
hemodynamic improvement does not ensure long-term
therapeutic benefit, and this has contributed to a de-
emphasis on hemodynamic improvement as a therapeutic
goal. They have also led a large number of physicians to
Abbreviations and Acronyms
cAMP 5 cyclic adenosine monophosphate
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Figure 1. Cyclic adenosine monophosphate (cAMP)-mediated signaling in cardiac myocytes. Cyclic adenosine monophosphate generated
by adenylate cyclase activates cAMP-dependent protein kinase (PK-A), some of which is in the cytosol and some of which is bound to
intracellular membranes by anchoring proteins (AKAPs). Proteins phosphorylated by cAMP-dependent protein kinase include L-type and
ryanodine (Ry)-sensitive Ca21 channels in the sarcolemma and sarcoplasmic reticulum, respectively; phospholamban (PL), which interacts
with the Ca21-transporting adenosine triphosphatase (SERCA2) of the sarcoplasmic reticulum; troponin (Tn) I, complexed with troponin
C, troponin T, tropomyosin (TM) and actin in the thin filaments, and transcription factors such as cAMP-response element-binding
protein (CREB), whose phosphorylation is dependent upon the translocation of cAMP-dependent protein kinase from the cytosol to the
nucleus. ATP 5 adenosine triphosphate.
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conclude that agents that increase contractility have adverse
effects on survival in patients with heart failure.
SHIFTING THE FOCUS FROM INOTROPY TO cAMP
When examined carefully, the latter conclusion presents
serious problems. Cyclic adenosine monophosphate has
many important actions in cardiac myocytes apart from
those involved in inotropic responses. The regulation of
gene transcription by CREB phosphorylation and its im-
portance in maintaining normal myocardial function and
structure were noted earlier (11). Phosphorylation by
cAMP-dependent protein kinase also alters the activity of
glycogen synthase and phosphorylase kinase so as to stim-
ulate glycogen hydrolysis; its phosphorylation of beta-
adrenergic receptors and R subunits of cAMP-dependent
protein kinase serves an autoregulatory function for these
pathways (31–33). In view of these diverse actions, the basis
upon which the increased mortality in patients treated with
beta-adrenergic receptor agonists and PDE3 inhibitors can
be ascribed specifically to the activation of molecular mech-
anisms involved in their inotropic effects must be ques-
tioned. There are, in fact, several reasons for believing the
increased mortality is not linked mechanistically at the
molecular level to increased contractility. For one, hemody-
namic responses to beta-adrenergic receptor agonists and
PDE3 inhibitors are immediate, whereas increases in mor-
tality require months to demonstrate. Furthermore, with-
drawal of PDE3 inhibitors after chronic administration is
not accompanied by any diminution in contractility (22).
This observation is not surprising, given that the inotropic
efficacy of PDE3 inhibitors correlates inversely with the
severity of the cardiomyopathy and that the severity of the
cardiomyopathy progresses with time (34). But the fact that
survival is adversely affected despite a loss of inotropic
efficacy makes it difficult to conclude that the increased
mortality in patients treated with beta-adrenergic receptor
agonists and PDE3 inhibitors is inextricably tied to the
increase in contractility these agents elicit. This difficulty is
heightened by the fact that digoxin, an inotropic agent
whose mechanism of actions does not involve cAMP-
mediated signal transduction, does not increase cardiovas-
cular mortality in patients with heart failure (35).
For all these reasons, it may be preferable to regard the
adverse effects of beta-adrenergic receptor agonists and
PDE3 inhibitors in patients with heart failure as a function
of the increase in intracellular cAMP content they generate
rather than as a consequence of the mechanisms involved in
inotropic responses (Fig. 2). From this perspective, in-
creased mortality would be viewed as the net result of the
multiple effects of a nonselective increase in the phosphor-
ylation of literally dozens of substrates of cAMP-dependent
protein kinase involved in diverse intracellular functions in
cardiac myocytes. This interpretation has two important
corollaries. The first is that although the overall balance of
the effects of raising intracellular cAMP content in cardiac
myocytes is harmful, it is possible that some of the individ-
ual effects are beneficial. It may be, for example, that
inotropic responses are desirable but are outweighed by an
increase in ventricular arrhythmias. The second is that the
reduction in survival in patients treated with beta-adrenergic
receptor agonists and PDE3 inhibitors might be attributable
to the phosphorylation of a subset of protein substrates that
either is separate from or only partially overlaps with the
subset of protein substrates to which potentially desirable
effects on contractility and gene transcription are attribut-
able (Fig. 3). Increases in the phosphorylation of sarcolem-
mal Ca21 channels, troponin I and CREB, for example,
might augment contractility and slow or reverse the pro-
Figure 2. Alternative interpretations of the results of clinical trials
of beta-adrenergic receptor agonists and phosphodiesterase-3 in-
hibitors. The “conventional” interpretation is that increasing in-
tracellular cyclic adenosine monophosphate (cAMP) content
causes a short-term increase in contractility that causes a reduction
in long-term survival. The alternative interpretation proposed
herein is that the increase in intracellular cAMP content may
increase contractility and increase mortality through separate
mechanisms.
Figure 3. Schematic representation of the substrates of cyclic
adenosine monophosphate (cAMP)-dependent protein kinase.
Substrates of cAMP-dependent protein kinase may be thought of
as belonging to the subset whose phosphorylation contributes to
the increased mortality seen with beta-adrenergic receptor agonists
and PDE3 inhibitors and/or to the subset whose phosphorylation
contributes to increased contractility. The extent of overlap be-
tween the two subsets is unknown.
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gression of myocardial dilation without adversely affecting
mortality, whereas increases in the phosphorylation of
phospholamban, sarcoplasmic reticulum Ca21 channels,
glycogen synthase and phosphorylase kinase might reduce
survival by increasing ventricular ectopic activity and deplet-
ing myocardial energy reserves. If this is the case, interven-
tions that could increase the phosphorylation of “beneficial”
substrates without increasing the phosphorylation of “harm-
ful” ones might allow inotropic and other benefits to be
achieved without the concomitant increase in mortality seen
with nonselective increases in cAMP-stimulated protein
phosphorylation.
In the absence of a clearly identified mechanism to which
the increased mortality that accompanies increases in intra-
cellular cAMP content can be ascribed, the possibility that
separate substrates of cAMP-dependent protein kinase
contribute to beneficial and harmful responses is a matter of
speculation. But the difficulties noted earlier in attributing
the increase in mortality in patients treated with beta-
adrenergic receptor agonists and PDE3 inhibitors to mech-
anisms involved in inotropic responses certainly makes this
speculation plausible. Also, increases in our understanding
of cAMP-mediated signal transduction in cardiac myocytes
now offer several opportunities for selectively increasing the
phosphorylation of specific substrates of cAMP-dependent
protein kinase, at least one of which may be involved in a
recently reported therapeutic approach.
NEW THERAPEUTIC DIRECTIONS
One opportunity for selectively modulating the phosphory-
lation of different substrates of cAMP-dependent protein
kinase relates to the fact that the cAMP content in different
intracellular compartments of mammalian cardiac myocytes
can be differentially regulated. Some of this differential
regulation takes place at the receptor level. Occupancy of
beta1-adrenergic receptors by their agonists results in an
increase in both cytosolic and membrane-bound cAMP
content; the same is true for beta2-adrenergic receptors, but
in the latter case the increase in membrane-bound cAMP
content is significantly lower than is seen when beta1-
adrenergic receptors are occupied, and when prostaglandin
E1 receptors (which, like beta-adrenergic receptors, are
coupled by G-alphas to adenylate cyclase) are occupied by
their agonists, the increase in cAMP content is restricted to
the cytosol (36–39). Exactly how compartmental cAMP
levels are selectively regulated at the receptor level is
unclear—coupling of beta1- and beta2-adrenergic receptors
to different classes of G proteins may be involved (40)—but
the result is a differential activation of cAMP-dependent
protein kinase in functional compartments of cardiac myo-
cytes and a consequent phosphorylation of different sub-
strates. Increases in the amplitude of intracellular Ca21
transients in response to beta1-adrenergic receptor agonists
correlate with changes in membrane-bound cAMP content,
and are accompanied by increases in phospholamban phos-
phorylation and the rate of relaxation; occupancy of beta2-
adrenergic receptors by their agonists, in contrast, results in
an increase in the amplitude of intracellular Ca21 transients
that does not correlate with changes in cAMP content and
occurs without increases in phospholamban phosphoryla-
tion or relaxation rates (38,41,42). In fact, the stimulation of
Ca21 influx through dihydropyridine-sensitive channels by
beta2-adrenergic receptor agonists, although dependent on
cAMP-dependent protein kinase activity, occurs without
any detectable change in total intracellular cAMP content
(43,44). The latter observation is evidence that changes in
intracellular cAMP content in response to receptor occu-
pancy can be localized with exquisite precision.
This compartmental regulation of cAMP-dependent
protein phosphorylation may be important in heart failure
for several reasons. The selective down-regulation of beta1-
adrenergic receptors in failing myocardium may cause a
selective decrease in membrane-associated cAMP content
(2,45). Thus, the pattern of proteins phosphorylated in
failing myocardium in response to beta-adrenergic receptor
agonists may differ significantly from what is seen in normal
tissue. Compartmentation may also be relevant to the
recently reported use of the combination of metoprolol and
enoximone in patients with advanced contractile failure
(46). Selective beta1-adrenergic receptor antagonism in
conjunction with nonselective PDE3 inhibition might pro-
duce what would amount to a selective potentiation of
beta2-stimulated responses, with a resulting pattern of
protein phosphorylation that would differ from that ob-
tained with nonselective beta-adrenergic receptor stimula-
tion or nonselective PDE3 inhibition alone. For reasons
noted above, this might lead to an increase in contractility
without an increase in Ca21 accumulation by the sarcoplas-
mic reticulum; if the latter is arrhythmogenic, this might
prove beneficial. Compartmentally selective pharmacologic
manipulation of cAMP-mediated signal transduction might
also be achieved through selective PDE3 inhibition. PDE3
activity is found both in the cytosol and associated with
intracellular membranes in cardiac myocytes, and there is
evidence that cytosolic and membrane-bound forms of
PDE3 are separate molecular species (47). Selective inhibi-
tion of the specific compartmental isoform could lead to a
selective increase in compartmental cAMP content and
kinase activity. Determining whether the differences be-
tween cytosolic and membrane-associated forms of PDE3
at the molecular level are sufficient to make selective
inhibition of the membrane-associated isoform feasible is a
central issue.
A second opportunity for selectively increasing the phos-
phorylation of different substrates of cAMP-dependent
protein kinase involves the different isoforms of the enzyme,
of which two classes have been described (for review, see
[1]). The two classes, designated type I and type II, differ
with respect to intracellular localization, activation and
regulation, and cyclic nucleotide analogs that preferentially
activate one or the other class of isoform have been
321JACC Vol. 34, No. 2, 1999 Movsesian
August 1999:318–24 Inotropy and cAMP
identified (48–50). The use of these analogs has demon-
strated that the two isoforms serve different functions. In T
lymphocytes, for example, proliferation is inhibited by
activation of the type I kinase but not by activation of type
II kinase; lipolytic effects in adipocytes are attributable to
activation of RII-associated C subunits (51–53). Selective
activation of type I or type II isoforms, both of which are
present in cardiac myocytes (54), may offer a means of
selectively altering the phosphorylation of the substrates of
cAMP-dependent protein kinase. Whether the two iso-
forms phosphorylate different substrates in cardiac myo-
cytes—and, if so, whether selective activation of the appro-
priate isoforms can be used to separate beneficial and
harmful effects—will be an important area for future exper-
iments.
The possibilities for selectively increasing the phosphor-
ylation of targeted substrates discussed rely upon selective
stimulation of cAMP-dependent protein kinase activity.
Another possibility involves the inhibition of the protein
phosphatases that dephosphorylate these substrates (for
review, see [55,56]). For many years it was believed that
protein phosphatases are relatively few in number and
relatively nonspecific with respect to substrates, so that
opportunities for selectivity seemed unlikely. More recently,
though, the number of different phosphatases that have
been identified has increased dramatically, and it has be-
come clear that noncatalytic subunits of some of these
phosphatases can confer exquisite substrate specificity,
through either substrate recognition or intracellular target-
ing. If the substrates of cAMP-dependent protein kinase are
dephosphorylated by different protein phosphatases, it may
be possible to selectively increase the phosphorylation of
substrates contributing to the beneficial effects of increases
in cAMP content by selectively inhibiting the protein
phosphatases to which they are coupled (Fig. 4).
There are several reasons to be optimistic about phospha-
tase inhibition as a therapeutic approach in heart failure.
First, protein phosphatases have very different patterns of
tissue expression, with some being expressed abundantly
and somewhat selectively in myocardium (57). Cardiac-
specific phosphatase inhibition may be feasible. Further-
more, phosphatase inhibition has been shown to result in
major inotropic effects that, unlike those of PDE3 inhibi-
tion, are not diminished in magnitude in failing myocar-
dium (58). Also, more recently, studies in animals have
pointed to a role for one phosphatase, calcineurin, in the
pathogenesis of cardiomyopathies. Calcineurin inhibitors
prevent the development of myocardial hypertrophy in
animals predisposed to this condition because of abnormal
expression of contractile proteins; animals overexpressing
calcineurin develop myocardial hypertrophy (59,60). Phos-
phatase inhibition thus offers the prospect of not merely
improving the outcome in patients with cardiomyopathies
but of actually preventing or reversing the underlying
myocardial pathology.
CONCLUSIONS
The recognition that beta-adrenergic receptor agonists and
PDE3 inhibitors have adverse effects on survival in patients
with heart failure has profoundly influenced thinking about
this syndrome and its treatment. What remains unclear,
however, is whether this reduction in survival is mechanis-
tically linked to the inotropic actions of these drugs or
results from the activation of other cAMP-mediated pro-
cesses in cardiac myocytes. A shift in focus from inotropy to
cAMP-mediated signaling and a consideration of the mo-
lecular mechanisms involved in this signaling opens the
door to several new therapeutic strategies through which
these mechanisms might be modulated selectively, possibly
allowing the hemodynamic and other potentially beneficial
effects of increases in intracellular cAMP content to be
achieved without the concomitant reduction in survival seen
with currently available agents.
Acknowledgments
The author is grateful to Drs. Edward Gilbert and Dale G.
Renlund for their valuable critiques.
Reprint requests and correspondence: Dr. Matthew A. Movse-
sian, Cardiology Division, 4A-100 SOM, University of Utah
Health Sciences Center, 50 North Medical Drive, Salt Lake City,
Utah 84132. E-mail: matthew.movsesian@hsc.utah.edu.
REFERENCES
1. Movsesian MA. cAMP-mediated signal transduction in heart failure:
molecular pathophysiology and therapeutic implications. J Invest Med
1997;45:432–40.
2. Bristow MR, Ginsburg R, Umans V, et al. b1- and b2-adrenergic-
receptor subpopulations in nonfailing and failing human ventricular
myocardium: coupling of both receptor subtypes to muscle contraction
and selective b1-receptor down-regulation in heart failure. Circ Res
1986;59:297–309.
3. Feldman AM, Cates AE, Veazey WB, et al. Increase in the 40,000-
Figure 4. Selective inhibition of dephosphorylation. Four sub-
strates of cyclic adenosine monophosphate (cAMP)-dependent
protein kinase—troponin I (TnI), phospholamban (PL), glycogen
synthase (Gly Syn) and cAMP-response element-binding protein
(CREB)—are represented hypothetically coupled to separate pro-
tein phosphatases (designated PP-T, PP-P, PP-G and PP-C).
Selective inhibition of PP-T would result in a selective increase in
the phosphorylation of troponin I. PK-A 5 protein kinase.
322 Movsesian JACC Vol. 34, No. 2, 1999
Inotropy and cAMP August 1999:318–24
mol wt pertussis toxin substrate (G protein) in the failing human heart.
J Clin Invest 1988;82:189–97.
4. Ungerer M, Bo¨hm M, Elce JS, et al. Altered expression of
b-adrenergic receptor kinase and b1-adrenergic receptors in the failing
human heart. Circulation 1993;87:454–63.
5. Niroomand F, Lutz S, Mura R, Baltus D. Increased activity of
membrane-associated nucleoside diphosphate kinase leads to inhibi-
tion of adenylyl cyclase in membranes from failing human myocar-
dium. Circulation 1997;96:I-495–6.
6. Sculptoreanu A, Rotman E, Takahashi M, et al. Voltage-dependent
potentiation of the activity of cardiac L-type calcium channel alpha 1
subunits due to phosphorylation by cAMP-dependent protein kinase.
Proc Natl Acad Sci USA 1993;90:10135–9.
7. Witcher DR, Kovacs RJ, Schulman H, et al. Unique phosphorylation
site on the cardiac ryanodine receptor regulates calcium channel
activity. J Biol Chem 1991;266:11144–52.
8. James P, Inui M, Tada M, et al. Nature and site of phospholamban
regulation of the Ca21 pump of the sarcoplasmic reticulum. Nature
1989;342:90–2.
9. Tobacman LS. Thin filament-mediated regulation of cardiac contrac-
tion. Ann Rev Physiol 1996;58:447–81.
10. Hagiwara M, Brindle P, Harootunian A, et al. Coupling of hormonal
stimulation and transcription via the cyclic AMP-responsive factor
CREB is rate limited by nuclear entry of protein kinase A. Mol Cell
Biol 1993;13:4852–9.
11. Fentzke RC, Korcarz CE, Lang RM, et al. Dilated cardiomyopathy in
transgenic mice expressing a dominant-negative CREB transcription
factor in the heart. J Clin Invest 1998;101:2415–26.
12. Goldberg LI, Hsieh Y-Y, Resnekov L. Newer catecholamines for
treatment of heart failure and shock: an update on dopamine and
dobutamine. Prog Cardiovasc Dis 1977;19:327–40.
13. Dies F, Krell MJ, Whitlow P, et al. Intermittent dobutamine in
ambulatory patients with chronic cardiac failure (abstr). Circulation
1986;76:II-38.
14. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in
severe heart failure. Lancet 1990;336:1–6.
15. Komas N, Movsesian M, Kedev S, et al. cGMP-inhibited cyclic
nucleotide phosphodiesterases. In: Schudt C, Dent G, Rabe KF,
editors. Phosphodiesterase Inhibitors. San Diego (CA): Academic
Press, 1996:89–109.
16. Movsesian MA, Smith CJ, Krall J, et al. Sarcoplasmic reticulum-
associated cyclic adenosine 59-monophosphate phosphodiesterase ac-
tivity in normal and failing human hearts. J Clin Invest 1991;88:15–9.
17. Benotti JR, Grossman W, Braunwald E, et al. Hemodynamic assess-
ment of amrinone. N Engl J Med 1978;299:1373–7.
18. Baim DS, McDowell AV, Cherniles J, et al. Evaluation of a new
bipyridine inotropic agent—milrinone—in patients with severe con-
gestive heart failure. N Engl J Med 1983;309:748–56.
19. Sinoway LS, Maskin CS, Chadwick B, et al. Long-term therapy with
a new cardiotonic agent, WIN 47203: drug-dependent improvement
in cardiac performance and progression of the underlying disease. J Am
Coll Cardiol 1983;2:327–31.
20. Uretsky BF, Generalovich T, Reddy PS, et al. The acute hemody-
namic effects of a new agent, MDL 17,043, in the treatment of
congestive heart failure. Circulation 1983;67:823–8.
21. Jaski BE, Fifer MA, Wright RF, et al. Positive inotropic and
vasodilator actions of milrinone in patients with severe congestive heart
failure. J Clin Invest 1985;75:643–9.
22. DiBianco R, Shabetai R, Silverman BD, et al. Oral amrinone for the
treatment of chronic congestive heart failure: results of a multicenter
randomized double-blind and placebo-controlled withdrawal study.
J Am Coll Cardiol 1984;4:855–66.
23. Massie B, Bourassa M, DiBianco R, et al. Long-term oral adminis-
tration of amrinone for congestive heart failure: lack of efficacy in a
multicenter controlled trial. Circulation 1985;71:963–71.
24. DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral
milrinone, digoxin, and their combination in the treatment of patients
with chronic heart failure. N Engl J Med 1989;320:677–83.
25. Uretsky BF, Jessup M, Konstam MA, et al. Multicenter trial of oral
enoximone in patients with moderate to moderately severe congestive
heart failure. Lack of benefit compared with placebo. Circulation
1990;82:774–80.
26. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on
mortality in severe chronic heart failure. N Engl J Med 1991;325:
1428–75.
27. Nony P, Boissel J-P, Lie`vre M, et al. Evaluation of the effect of
phosphodiesterase inhibitors on mortality in chronic heart failure
patients. Eur J Clin Pharmacol 1994;46:191–6.
28. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of
metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:
1441–6.
29. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on
morbidity and mortality in patients with chronic heart failure. N Engl
J Med 1996;334:1349–55.
30. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemody-
namic, left ventricular functional, and antiadrenergic effects of chronic
treatment with metoprolol versus carvedilol in the failing heart.
Circulation 1996;94:2817–25.
31. Exton JH. Mechanisms of hormonal regulation of hepatic glucose
metabolism. Diabetes Metab Rev 1987;3:163–83.
32. Benovic JL, Pike LJ, Cerione RA, et al. Phosphorylation of the
mammalian b-adrenergic receptor by cyclic AMP-dependent protein
kinase. Regulation of the rate of receptor phosphorylation and dephos-
phorylation by agonist occupancy and effects on coupling of the
receptor to the stimulatory guanine nucleotide regulatory protein.
J Biol Chem 1985;260:7094–101.
33. Erlichman J, Rosenfeld R, Rosen OM. Phosphorylation of a cyclic
adenosine 39:59-monophosphate-dependent protein kinase from bo-
vine cardiac muscle. J Biol Chem 1974;249:5000–3.
34. Bo¨hm M, Diet F, Feiler G, et al. Subsensitivity of the failing human
heart to isoprenaline and milrinone is related to b-adrenoceptor
downregulation. J Cardiovasc Pharmacol 1988;12:726–32.
35. The Digitalis Investigation Group. The effect of digoxin on mortality
and morbidity in patients with heart failure. N Engl J Med 1997;336:
525–33.
36. Hayes JS, Brunton LL, Mayer SE. Selective activation of particulate
cAMP-dependent protein kinase by isoproterenol and prostaglandin
E1. J Biol Chem 1980;255:5113–9.
37. Buxton IL, Brunton LL. Compartments of cyclic AMP and protein
kinase in mammalian cardiomyocytes. J Biol Chem 1983;258:
10233–9.
38. Xiao R-P, Hohl C, Altschuld R, et al. b2-Adrenergic receptor-
stimulated increase in cAMP in rat heart cells is not coupled to
changes in Ca21 dynamics, contractility, or phospholamban phosphor-
ylation. J Biol Chem 1994;269:19151–6.
39. Yabana H, Sasaki Y, Narita H, Nagao T. Subcellular fractions of cyclic
AMP and cyclic AMP-dependent protein kinase and the positive
inotropic effects of selective b1- and b2-adrenoceptor agonists in
guinea pig hearts. J Cardiovasc Pharmacol 1995;26:893–8.
40. Xiao R-P, Ji X, Lakatta EG. Functional coupling of the b2-
adrenoceptor to a pertussis toxin-sensitive G protein in cardiac
myocytes. Mol Pharmacol 1995;47:322–9.
41. Hohl CM, Li Q. Compartmentation of cAMP in adult canine
ventricular myocytes. Relation to single-cell free Ca21 transients.
Circulation 1991;69:1369–79.
42. Xiao R-P, Lakatta EG. b1-adrenoceptor stimulation and b2-
adrenoceptor stimulation differ in their effects on contraction, cytosolic
Ca21, and Ca21 current in single rat ventricular cells. Circ Res
1993;73:286–300.
43. Altschuld RA, Starling RC, Hamlin RL, et al. Response of failing
canine and human heart cells to b2-adrenergic stimulation. Circulation
1995;92:1612–8.
44. Zhou Y-Y, Cheng H, Bogdanov KY, et al. Localized cAMP-
dependent signalling mediates b2-adrenergic modulation of cardiac
excitation-contraction coupling. Am J Physiol 1997;273:H1611–8.
45. Bo¨hm M, Reiger B, Schwinger RHG, Erdmann E. cAMP concen-
trations, cAMP dependent protein kinase activity, and phospholamban
in non-failing and failing myocardium. Cardiovasc Res 1994;28:1713–9.
46. Shakar SF, Abraham WT, Gilbert EM, et al. Combined oral positive
inotropic and beta-blocker therapy for treatment of refractory class IV
heart failure. J Am Coll Cardiol 1998;31:1336–40.
47. Smith CJ, Krall J, Manganiello VC, Movsesian MA. Cytosolic and
sarcoplasmic reticulum-associated low Km, cGMP-inhibited cAMP
phosphodiesterase in mammalian myocardium. Biochem Biophys Res
Commun 1993;190:516–21.
48. Ogreid D, Ekanger R, Suva RH, et al. Comparison of the two classes
of binding sites (A and B) of type I and type II cyclic-AMP-dependent
323JACC Vol. 34, No. 2, 1999 Movsesian
August 1999:318–24 Inotropy and cAMP
protein kinases by using cyclic nucleotide analogs. Eur J Biochem
1989;181:19–31.
49. Dostmann WRG, Taylor SS, Genieser H-G, et al. Probing the cyclic
nucleotide binding sites of cAMP-dependent protein kinases I and II
with analogs of adenosine 39,59-cyclic phosphorothioates. J Biol Chem
1990;265:10484–91.
50. Gjertsen BT, Mellgren G, Otten A, et al. Novel (Rp)-cAMPS analogs
as tools for inhibition of cAMP-kinase in cell culture. J Biol Chem
1995;270:20599–607.
51. Skålhegg BS, Landmark BF, Døskeland SO, et al. Cyclic AMP-
dependent protein kinase type I mediates the inhibitory effects of
39,59-cyclic adenosine monophosphate on cell replication in human T
lymphocytes. J Biol Chem 1992;267:15707–14.
52. Laxminarayana D, Berrada A, Kammer GM. Early events of human T
lymphocyte activation are associated with type I protein kinase A
activity. J Clin Invest 1993;92:2207–14.
53. Beebe SJ, Holloway R, Rannels SR, Corbin JD. Two classes of cAMP
analogs which are selective for the two different cAMP-binding sites of
type II protein kinase demonstrate synergism when added together to
intact lymphocytes. J Biol Chem 1984;259:3539–47.
54. Corbin JD, Sugden PH, Lincoln TM, Keely SL. Compartmentaliza-
tion of adenosine 39:59-monophosphate and adenosine 39:59-
monophosphate-dependent protein kinase in heart tissue. J Biol Chem
1977;252:3854–61.
55. Mumby MC, Walter G. Protein serine/threonine phosphatases: struc-
ture, regulation and functions in cell growth. Physiol Rev 1993;73:
673–99.
56. Wera S, Hemmings BA. Serine/threonine protein phosphatases.
Biochem J 1995;311:17–29.
57. McCright B, Virshup DM. Identification of a new family of protein
phosphatase 2A regulatory subunits. J Biol Chem 1995;270:26123–8.
58. Linck B, Boknik P, Knapp J, et al. Effects of cantharidin on force of
contraction and phosphatase activity in nonfailing and failing human
hearts. Br J Pharmacol 1996;119:545–50.
59. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent
transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215–
28.
60. Sussman MA, Lim HW, Gude N, et al. Prevention of cardiac
hypertrophy in mice by calcineurin inhibition. Science 1998;281:
1690–3.
324 Movsesian JACC Vol. 34, No. 2, 1999
Inotropy and cAMP August 1999:318–24
